The LFB laboratory is currently experiencing supply tensions on several of its blood derived from blood. In order to limit the impact of tensions and ensure fair distribution of these drugs, the LFB, in accordance with the ANSM, has set up a limitation of sales of some of its blood derived from blood. In addition, therapeutic alternatives are available in sufficient quantity to ensure continuity of care.
The ANSM publishes recommendations, in accordance with the health sector healths rare hemorrhagic diseases (MHEMO) and the network allows (exchange and research platform on blood -derived drugs and recombinant analogs), to support professionals in the use of these alternatives.
Tensions (or even ruptures for certain dosages) follow a temporary decrease in production to allow the upgrading of certain equipment on the manufacturing site. This leads to delays in supply for several drugs derived from blood, likely to extend until mid-2026 in some cases.
Medicines concerned
- Somlotine (Anthrombine III I HIII)
- Alfalastin (alpha-1-antitrypsine)
- Betafact (IX Coagulation or Fix factor)
- Factane (factor VIII of coagulation FVIII)
- Clairyg and tegeline (intravenous human immunoglobulins or IG IV)
- Clottafact (fibrinogen)
- Protexel (Prostéine C)
- Vialebex (albumine)
- Wilfactin (factor von willebrand or fvw)
Recommendations to healthcare professionals for products whose alternatives have specificities
For patients receiving Wilfactin (FVW) in preventive treatment, needs may be covered and access to treatment remains guaranteed.
For the management of treatments at the request of hemorrhagic episodes in patients with Willebrand’s disease, including for patients to be operated, the ANSM invites health professionals to provide other laboratories.
If an alternative to Wilfactin is envisaged, the choice of the most suitable treatment returns to the reference center carrying out the patient’s monitoring. The dose and frequency should be adjusted according to the patient’s profile and their state of health.
In any case, the ANSM invites health professionals to refer to the Summary of product characteristics (RCP) of the drugs concerned.
- Clottafact (fibrinogen)
If an alternative to the clottafact must be used, the ANSM recalls health professionals to be particularly vigilant: these drugs have dosages and methods of conservation, reconstruction and administration different from each other. Consult the guide for proper use of fibrinogen-based specialties and systematically refer to RCP.
Source: ANSM news from 07/03/2025
